FORT WORTH, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx(R) . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.
“The physicians that have contacted me have experienced outstanding clinical efficacy, particularly on diabetic and arterial ulcers when using CellerateRx(R),” states Dr. Larry Baratta, VP of Medical Affairs for Wound Care Innovations. “They also commented on the reduction of pain as noted by their patients with arterial ulcers while achieving wound resolution.”
For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com
About Wound Management Technologies, Inc.
Safe Harbor Statement:
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
CONTACT: Shareholder Relations-Communications, +1-954-357-0614
Web site: http://www.woundmanagementtechnologies.com/
